Fiche publication
Date publication
juillet 2018
Journal
Journal of autoimmunity
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BONNOTTE Bernard
,
Dr FACY Olivier
,
Pr ORTEGA DEBALLON Pablo
Tous les auteurs :
Audia S, Moulinet T, Ciudad-Bonté M, Samson M, Facy O, Ortega-Deballon P, Saas P, Bonnotte B
Lien Pubmed
Résumé
Innate lymphoid cells (ILCs) have been characterized as innate immune cells capable to modulate the immune response in the mucosae. Human ILCs have been rarely described in secondary lymphoid organs except in tonsils. Moreover, their function and phenotype in human secondary lymphoid organs during autoimmune diseases have never been studied. We took advantage of splenectomy as a treatment of immune thrombocytopenia (ITP) to describe and compare splenic ILC from 18 ITP patients to 11 controls. We first confirmed that ILC3 represented the most abundant ILC subset in human non-inflamed spleens, accounting for 90% of total ILC, and that they were mostly constituted of NKp44 cells. On the contrary, proportions of ILC1 and ILC2 in spleens were lower than in blood. Splenic IL-2- and IFN-γ-producing ILC1 were increased in ITP. While the frequencies of total splenic ILC3 were similar in the two groups, splenic GM-CSF-producing ILC3 were increased in ITP. This is the first description of human ILC in a major secondary lymphoid organ during an autoimmune disease, ITP. We observed an expansion of splenic ILC1 that could participate to the Th1 skewing, while the increased production of GM-CSF by splenic ILC3 could stimulate splenic macrophages which play a key role in ITP pathophysiology.
Mots clés
Immune thrombocytopenia, Innate lymphoid cells, Spleen
Référence
J. Autoimmun.. 2018 Jul 23;:
